Business Context and Reporting Period
This Form 8-K reports a capital raise event for DanDrit Biotech USA, Inc. (referred to in metadata as Lunai Bioworks Inc.) with a report date of October 27, 2014, covering a closing event on October 23, 2014. The company is a Delaware corporation with principal executive offices in Copenhagen, Denmark.
Key Financial Metrics
- Transaction Type: Registered direct placement of common stock.
- Shares Sold in Closing: 589,490 shares.
- Price Per Share: $5.00.
- Gross Proceeds (Closing): $2,947,450.
- Total Offering Progress: 1,034,790 shares sold to date for total gross proceeds of $5,173,950.
- Placement Agent Fees: $25,000 paid in cash for counsel reimbursement (part of up to 1% accountable expense reimbursement).
Material Changes
The filing details the completion of a specific tranche of a "best efforts" public offering. The company has now sold approximately 43% of the maximum 2,400,000 shares authorized in the offering. The filing does not provide comparative financial data (revenue, profit, or cash flow) for prior periods as this is a transactional report rather than a periodic financial statement.
Guidance, Outlook, and Risks
Use of Proceeds: The company intends to use the gross proceeds in accordance with the "Use of Proceeds" section described in the Registration Statement on Form S-1 (File No. 333-193965).
Offering Status: The offering remains open under a "best efforts" basis, with the potential to sell up to 1,365,210 additional shares to reach the 2,400,000 share cap.
Investor Verification Checklist
- Verify the full text of the Placement Agency Agreement (Exhibit 1.1) for additional fee structures or conditions.
- Review the "Use of Proceeds" section in the August 12, 2014 Prospectus to confirm capital allocation plans.
- Confirm the current share count and dilution impact based on the 1,034,790 shares sold to date.
- Check for any subsequent filings regarding the completion or termination of the remaining "best efforts" offering.